Update on Biomarkers in Renal Cell Carcinoma
American Society of Clinical Oncology Educational Book · 2024-01 · 44 (2)
DOI: 10.1200/edbk_430734 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Society of Clinical Oncology Educational Book, 2024-01. Verfasst von Renée M Saliby und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Biomedical Research. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 85 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibitors have significantly transformed the treatment paradigm for metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving remarkable deep and durable responses. However, given the multiple ICI-containing, standard-of-care regimens approved for RCC, identifying biomarkers that predict therapeutic response and resistance is of critical importance. Although tumor-intrinsic features such as pathological characteristics, genomic alterations, and transcriptional signatures have been extensively investigated, they have yet to provide definitive, robust predictive biomarkers. Current research is exploring host factors through in-depth characterization of the immune system. Additionally, innovative technological approaches are being developed to overcome challenges presented by existing techniques, such as tumor heterogeneity. Promising avenues in biomarker discovery include the study of the microbiome, radiomics, and spatial transcriptomics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
- Yale Center of Cellular and Molecular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT.
- Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
ORCID-Profile: Renée M Saliby, Eddy Saad, Soki Kashima, David A Braun
Zitieren
APA
Saliby, R. M., Saad, E., Kashima, S., Schoenfeld, D. A., & Braun, D. A. (2024). Update on Biomarkers in Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book, 44(2). https://doi.org/10.1200/edbk_430734
Vancouver
Saliby RM, Saad E, Kashima S, Schoenfeld DA, Braun DA. Update on Biomarkers in Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book. 2024;44(2). doi:10.1200/edbk_430734
BibTeX
@article{Saliby2024,
author = {Saliby, Renée M and Saad, Eddy and Kashima, Soki and Schoenfeld, David A and Braun, David A},
title = {Update on Biomarkers in Renal Cell Carcinoma},
journal = {American Society of Clinical Oncology Educational Book},
year = {2024},
volume = {44},
number = {2},
doi = {10.1200/edbk_430734}
}
EUVIMED